Standard Treatment Regimen for Drug‑Susceptible Tuberculosis

Preferred Regimen

Intensive Phase (First 2 Months)

Continuation Phase (Months 3‑6)

Administration Schedule

Pyridoxine (Vitamin B6) Supplementation

Alternative Regimens (Less Preferred)

Critical Pitfalls to Avoid

Treatment of Tuberculosis

Introduction to Treatment Regimens

• The American Thoracic Society and the European Respiratory Society recommend a 6-month regimen consisting of 2 months of isoniazid, rifampin, pyrazinamide, and ethambutol (2HRZE) followed by 4 months of isoniazid and rifampin (4HR) for drug-susceptible tuberculosis 4, 5, 6

Initial Intensive Phase (2 Months)

• The Centers for Disease Control and Prevention recommend using four drugs: isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E) for the first 2 months 4, 5, 6
• The Infectious Diseases Society of America suggests the following dosing for adults: isoniazid 5 mg/kg (maximum 300 mg daily) 5, rifampin 10 mg/kg (maximum 600 mg daily) 5, pyrazinamide 35 mg/kg daily for patients <50 kg or 2.0 g daily for patients >50 kg 6, and ethambutol 15 mg/kg daily 5, 6

Continuation Phase (4 Months)

• The American College of Chest Physicians recommends using two drugs: isoniazid and rifampin for 4 months after completing the intensive phase 4, 5, 6
• The World Health Organization suggests extending the continuation phase to 7 months (total 9 months of treatment) in specific situations, such as patients with cavitary pulmonary TB on initial chest X-ray AND positive sputum culture at completion of 2 months of treatment 7, 5

Administration Schedule

• The European Respiratory Society strongly recommends daily dosing for both intensive and continuation phases 4, 5
• The Centers for Disease Control and Prevention suggest using Directly Observed Therapy (DOT) rather than self-administered therapy for all TB patients 5, 6, 7

Special Populations

• The American Thoracic Society recommends using the same 6-month regimen (2HRZE/4HR) but administering daily or three times weekly—never twice weekly if CD4 <100 cells/μL for HIV-infected patients 8
• The Infectious Diseases Society of America suggests adding adjunctive corticosteroids (dexamethasone or prednisone) for the first 6-8 weeks in TB meningitis, TB pericarditis, and spinal TB with cord compression 4

Pyridoxine Supplementation

• The American College of Chest Physicians recommends adding pyridoxine (vitamin B6) 25-50 mg daily to all patients receiving isoniazid who are at risk for neuropathy, including pregnant women, breastfeeding infants, HIV-infected patients, and patients with diabetes, alcoholism, malnutrition, or chronic renal failure 5, 6

Monitoring Treatment Response

• The European Respiratory Society recommends monitoring response with follow-up sputum smear microscopy and culture at completion of the intensive phase (2 months) and at treatment completion 4
• The Centers for Disease Control and Prevention suggest performing baseline hepatic function tests (AST/ALT and bilirubin) in HIV-infected patients, pregnant women, patients with history of chronic liver disease, and regular alcohol users 9

Guideline for Treatment of Drug‑Sensitive Pulmonary Tuberculosis

Regimen Overview

• The preferred regimen for newly diagnosed drug‑sensitive pulmonary TB is a 6‑month course: a 2‑month intensive phase with four daily drugs (isoniazid, rifampicin, pyrazinamide, ethambutol) followed by a 4‑month continuation phase with two daily drugs (isoniazid and rifampicin) 10, 11.

Dosage Details (Intensive Phase)

• Isoniazid 5 mg/kg (≈300 mg) given daily 10.
• Rifampicin 10 mg/kg daily (≈600 mg for patients ≥ 50 kg, 450 mg for < 50 kg) 10.
• Ethambutol 15 mg/kg given daily 10.

Dosage Details (Continuation Phase)

• Isoniazid 5 mg/kg (≈300 mg) given daily 10.
• Rifampicin 10 mg/kg (≈600 mg) given daily 10.

Extension of Treatment Duration

• Patients with cavitary disease on the initial chest radiograph who remain culture‑positive after 2 months should receive an extended continuation phase of 7 months (total 9 months of therapy) 10, 11.

Directly Observed Therapy (DOT)

• DOT is recommended for all TB patients to ensure treatment completion and prevent the emergence of drug resistance 10, 11.
• When DOT is used, a 5‑days‑per‑week schedule is an acceptable alternative to daily dosing, based on extensive clinical experience 10.

Pyridoxine (Vitamin B6) Supplementation

• Pyridoxine 25–50 mg daily should be co‑administered with isoniazid for individuals at risk of neuropathy, including pregnant women, lactating women, patients with chronic renal failure, and other high‑risk groups 10, 11, 12.
• If peripheral neuropathy develops, the pyridoxine dose should be increased to 100 mg daily 10.

Intermittent (Non‑Daily) Regimens – When They May Be Considered

• A three‑times‑per‑week regimen may be considered only for HIV‑negative patients with low relapse risk (non‑cavitary disease and/or smear‑negative) after an initial 2‑week daily period 12.
• Missed doses in intermittent regimens can lead to treatment failure and acquired drug resistance, so they must be used with caution 10, 11.

Intermittent Regimens – Contraindications

• A twice‑weekly regimen is contraindicated in HIV‑infected patients or in those with smear‑positive or cavitary disease because of a markedly increased risk of failure and relapse 10, 11.

Special Considerations for HIV‑Positive Patients

• HIV‑positive patients receiving antiretroviral therapy should follow the standard 6‑month daily regimen 13.
• Intermittent regimens (twice or three times weekly) must never be used in HIV‑positive patients due to high rates of relapse and drug resistance 13.
• If an HIV‑positive patient is not on antiretroviral therapy during TB treatment, the continuation phase should be extended by an additional 3 months (total 9 months) 13.

Monitoring Treatment Response

• Obtain sputum smear and culture at baseline and then monthly until two consecutive specimens are negative 12.
• Perform baseline drug‑susceptibility testing for isoniazid, rifampicin, ethambutol, and pyrazinamide 12.

Standard Treatment Regimen for Drug‑Susceptible Tuberculosis

Regimen Overview

• The recommended regimen for newly diagnosed drug‑susceptible tuberculosis is a 6‑month course: an intensive phase of 2 months with four drugs (isoniazid, rifampin, pyrazinamide, ethambutol) taken daily, followed by a continuation phase of 4 months with isoniazid and rifampin taken daily. 14

Drug Dosing (Intensive Phase)

• Isoniazid 5 mg/kg (≈300 mg) daily; Rifampin 10 mg/kg (≈600 mg for patients ≥ 50 kg, 450 mg for < 50 kg) daily; Pyrazinamide 25 mg/kg daily; Ethambutol 15 mg/kg daily. All doses are administered daily during the 2‑month intensive phase. 14

Phase Durations

• The intensive phase comprises 56 directly observed doses over 8 weeks. 14, 15
• The continuation phase comprises 126 directly observed doses over 18 weeks (4 months). 14

Indications for Extending Therapy to 9 Months

• Patients who have both cavitary disease on the initial chest radiograph and a positive sputum culture at the end of the 2‑month intensive phase should receive an extended continuation phase of 7 months (total 9 months of therapy). 14, 15

Administration Practices

• Daily dosing is strongly preferred for both the intensive and continuation phases. 14
• Directly observed therapy (DOT) should be employed for all tuberculosis patients to ensure completion and prevent resistance. 14
• When DOT is used, a 5‑days‑per‑week schedule is an acceptable alternative to a 7‑days‑per‑week schedule, based on extensive clinical experience. 14, 15

Pyridoxine (Vitamin B6) Supplementation

• Mandatory pyridoxine supplementation of 25–50 mg daily is recommended for individuals at risk of peripheral neuropathy, including pregnant women, breastfeeding infants, HIV‑infected persons, patients with diabetes, alcoholism, malnutrition, chronic renal failure, and older adults. 14, 16
• If peripheral neuropathy develops during therapy, the pyridoxine dose should be increased to 100 mg daily. 14

Special Considerations for HIV‑Infected Patients

• HIV‑infected patients receiving antiretroviral therapy should be treated with the same standard 6‑month daily regimen (2 months HRZE / 4 months HR). 16
• Intermittent (twice‑ or thrice‑weekly) regimens must never be used in HIV‑infected patients because they are associated with high rates of relapse and acquired drug resistance. 16
• HIV‑infected patients not on antiretroviral therapy should have the continuation phase extended by an additional 3 months, resulting in a total of 9 months of therapy (2 months HRZE / 7 months HR). 16